Canagliflozin (Janssen Research & Development), developed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, raised the level of bad cholesterol in patients during clinical trials and may post heart risks, according to FDA and reported by Reuters.

dagfgaf

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Canagliflozin may not be good for the heart, FDA says

Newsletter